COMMUNIQUÉS West-GlobeNewswire

Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
22/05/2026
– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, May 22, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a [...]
Slim Tide Under Investigation: Critical Research Details Ingredients' Effectiveness for Metabolic & Digestive Support
23/05/2026
Slim Tide Consumer Research, Legitimacy Verification, Side Effects, Cost, Refund Policy, and Akkermansia Probiotic Capsule Ingredients for Gut Health Explained Largo, FL, May 22, 2026 (GLOBE NEWSWIRE) -- These [...]
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
22/05/2026
NOVATO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare [...]
GlycoPulse Claims Evaluated: Most Advanced Blood Sugar Support Ingredients for Healthy Glucose Management by Glyco Pulse
22/05/2026
GlycoPulse Ingredient Breakdown: Chromium Picolinate, Berberine HCL, Gymnema, Cinnamon, and Bitter Melon Blood Sugar Support Capsule with 180-Day Guarantee Largo, FL, May 22, 2026 (GLOBE NEWSWIRE) -- These statements [...]
XTL Announces Receipt of Staff Delist Determination from Nasdaq
22/05/2026
RAMAT GAN, ISRAEL, May 22, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a letter (the “Letter”) from The Listing [...]
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis
22/05/2026
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative [...]
European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European Union
22/05/2026
Joenja® (leniolisib) is first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3K δ ) syndrome (APDS) , a rare primary immunodeficiency, in adult and pediatric patients aged 12 [...]
NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
22/05/2026
PARIS and CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-clinical stage biotechnology company pioneering physics-based [...]
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
22/05/2026
STAFFORD, Texas, May 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) ("Greenwich" or the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO- [...]
NANOBIOTIX annonce l’exercice integral de l’option de surallocation, portant le produit de l'offre a 100 millions de dollars
22/05/2026
PARIS et CAMBRIDGE, Mass., 22 mai 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – « Nanobiotix » ou la « Société »), une société de biotechnologie au stade clinique et en phase avancée qui développe [...]
Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026
22/05/2026
SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 2-4, [...]
Organifi Parasite Cleanse Kit: The Most Effective Herbal Parasite Binding Detox Supplements on the Market
23/05/2026
Organifi Parasite Cleanse Capsules and Bind and Restore Tincture Ingredients, Mimosa Seed and Fulvic Acid Dosages, and 7-Day Herbal Cleanse Routine Explained San Diego, CA, May 22, 2026 (GLOBE NEWSWIRE) -- These [...]
Leo International Precision Health AG: Mr Leo Wang, Acquisition
22/05/2026
Leo International Precision Health AG: Mr Leo Wang, Acquisition Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them, 22. May [...]
Calidi Biotherapeutics Provides Required NYSE American Disclosure
23/05/2026
SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic medicines, today advised [...]
Leo International Precision Health AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
22/05/2026
Leo International Precision Health AG: Total Voting Rights Announcement Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 22. May 2026 / 22:00 [...]
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
22/05/2026
SAN CARLOS, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal [...]
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
22/05/2026
WAYNE, PA., May 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases [...]
SCYNEXIS Announces One-for-Eight Reverse Stock Split
22/05/2026
SCYNEXIS’s Common Stock to Begin Trading on Post-Split Adjusted Basis on June 1, 2026 JERSEY CITY, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS”), a clinical-stage biotechnology [...]
Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH
22/05/2026
Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH L’analyse intermédiaire [...]

Pages